The development is designed to assist with the World Health Organisation’s Treatment 2.0 strategy. Abbott is to create new therapies to allow for greater convenience to patients and doctors in third world countries, such as turning a current treatment into a powder format so that it does not need to be refrigerated and can be taken with food or water.
Dr Scott Brun, vice-president for infectious diseases at Abbott’s, says the new research programme “confirms our continued commitment to develop and provide effective, quality HIV medicines.”
Looking for a job in the pharmaceutical industry? Start by clicking here, now